Brochure | January 28, 2022

Sterile Formulation And Fill/Finish For Early-Phase Clinical Trials Of Insoluble Drugs

Source: Ascendia Pharma
iStock-1087219366-fill

As new gene therapy product development becomes patient targeted and complex, more products are being delivered by injection than orally. Development of parenteral dosage forms is more difficult than oral formulations. Chemical and physical stability are key considerations, viscosity is critical, and sterility is essential.

Ascendia’s team of scientists have decades of combined experience in sterile supplies for clinical trials, making them expert at solving the most difficult formulation challenges. In short, we consistently make the insoluble soluble.

access the Brochure!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Pharmaceutical Online? Subscribe today.

Subscribe to Pharmaceutical Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Pharmaceutical Online